Skip to main content
SpringerLink
Log in

Aclidinium/formoterol good value for money in COPD

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. The study was sponsored by AstraZeneca SA.

  2. forced expiratory volume in 1 second

Reference

  • Ramos M, et al. Cost versus utility of aclidinium bromide 400 microg plus formoterol fumarate dihydrate 12 microg compared to aclidinium bromide 400 microg alone in the management of moderate-to-severe COPD. ClinicoEconomics and Outcomes Research : 12 Sep 2016. Available from: URL: https://dx.doi.org/10.2147/CEOR.S107121

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Aclidinium/formoterol good value for money in COPD. PharmacoEcon Outcomes News 762, 9 (2016). https://doi.org/10.1007/s40274-016-3385-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-016-3385-6

Search

Navigation